Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells

European Journal of Clinical Investigation

Volumn 36, Issue 8, 2006, Pages 588-596

  Chang, C J ^b   Chiu, J H ^a,b   Tseng, L M ^a,b   Chang, C H ^b   Chien, T M ^b   Wu, C W ^a   Lui, W Y ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cyclin D1; ER ; Ferulic acid; HER2; MCF7

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIESTROGEN; CYCLIN D1; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR ALPHA; FERULIC ACID; FULVESTRANT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRASTUZUMAB; TRYPAN BLUE; WORTMANNIN;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL STIMULATION; CELL STRAIN MCF 7; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MITOGENESIS; MODULATION; MOLECULAR MECHANICS; ONCOGENE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SYNTHESIS; WESTERN BLOTTING;

ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; COUMARIC ACIDS; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGENS; MITOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 33746131931     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01676.x     Document Type: Article

References (35)

1. Baselga J, Norton L. Focus on breast cancer. Cancer Cell 2002;1:319-22.
2. Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT et al. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 2001;233:630-8.
3. Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 2004;61:2965-78.
4. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 2004;3:379-98.
5. Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity. Mol Cell Biol 1986;6:1729-40.
6. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-6.
7. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64:2343-6.
8. Molassiotis A, Scott JA, Kearney N, Pud D, Magri M, Selvekerova S et al. Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 2006;14:260-7.
9. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003;10:465-76.
10. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-13.
11. Powles T. Isoflavones and women's health. Breast Cancer Res 2004;6:140-2.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
13. Amato P, Christophe S, Mellon PL. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms. Menopause 2002;9:145-50.
14. Lau CB, Ho TC, Chan TW, Kim SC. Use of dong quai (Angelica sinensis) to treat peri- or post-menopausal symptoms in women with breast cancer: is it appropriate? Menopause 2005;12:734-40.
15. Yogeeta SK, Gnanapragasam A, Kumar SS, Subhashini R, Sathivel A, Devaki T. Synergistic interactions of ferulic acid with ascorbic acid: Its cardioprotective role during isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 2006;283:139-46.
16. Ronchetti D, Impagnatiello F, Guzzetta M, Gasparini L, Borgatti M, Gambari R et al. Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages. Eur J Pharmacol 2006;532:162-9.
17. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-53.
18. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 1986;83:2496-500.
19. Chiu JH, Kao HL, Wu LH, Chang HM, Lui WY. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry. J Clin Invest 1992;89:539-45.
20. Osborne CK, Shou J, Massarweh S, Schiff R. Cross-talk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865s-70s.
21. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37.
22. Kampa M, Alexaki VI, Notas G, Nifli AP, Nistikaki A, Hatzoglou A et al. Antiproliferative and apoptotic effects of selective phenolic acids on T47D human breast cancer cells: potential mechanisms of action. Breast Cancer Res 2004;6:R63-74.
23. Soule HD, Vazguez J, Long A, Albert S, Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 1973;51:1409-16.
24. Keydar I, Chen L, Karby S, Weiss FR, Delarea J, Radu M et al. Establishment and characterization of a cell line of human breast carcinoma origin. Eur J Cancer 1979;15:659-70.
25. Zheng ZY, Bay BH, Aw SE, Lin VC. A novel anti-estrogenic mechanism in progesterone receptor-transfected breast cancer cells. J Biol Chem 2005;280:17480-7.
26. Clarke RB. Steroid receptors and proliferation in the human breast. Steroids 2003;68:789-94.
27. Ansquer Y, Legrand A, Bringuier AF, Vadrot N, Lardeux B, Mandelbrot L et al. Progesterone induces BRCA1 mRNA decrease, cell cycle alterations and apoptosis in the MCF7 breast cancer cell line. Anticancer Res 2005;25:243-8.
28. Bodinet C, Freudenstein J. Influence of marketed herbal menopause preparations on MCF-7 cell proliferation. Menopause 2004;11:281-9.
29. Chan RY, Chen WF, Dong A, Guo D, Wong MS. Estrogen-like activity of ginsenoside Rg1 derived from Panax notoginseng. J Clin Endocrinol Metab 2002;87:3691-5.
30. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002;23:1831-8.
31. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor-2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004;10:3621-8.
32. Lewis JS, Vijayanathan V, Thomas TJ, Pestell RG, Albanese C, Gallo MA et al. Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2. Oncol Res 2005;15:113-28.
33. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 2005;23:2469-76.
34. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31.
35. Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 1999;340:1733-9.